2014 EASO Position Statement on the Use of Anti-Obesity Drugs

Hermann Toplak (1) , Euan Woodward (2) , Volkan Yumuk (3) , Jean-Michel Oppert (4, 5) , Jason C.G. Halford (5, 6) , Gema Frühbeck (7, 8, 9)

1 Department of Internal Medicine
2 European Association for the Study of Obesity
3 Division of Endocrinology, Metabolism and Diabetes
4 CHU Pitié-Salpêtrière [AP-HP]
5 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
6 University of Liverpool
7 Ciber Fisiopatologia Obesidad y Nutricion (CIBEROBN)
8 Department of Endocrinology and Nutrition
9 Obesity and Adipobiology Group

The European Association for the Study of Obesity (EASO) considers obesity to be a health, research, and societal priority [1]. It promotes the study of obesity. Moreover, the EASO facilitates and engages in actions that reduce the burden of unhealthy excess weight in Europe through prevention as well as management and prevent and combat the epidemic of obesity.

Domaines: Médicaments; Alimentation et Nutrition

Hermann Toplak, Euan Woodward, Volkan Yumuk, Jean-Michel Oppert, Jason C.G. Halford, et al.. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obes Facts, 2015, 8 (3), pp.166-174. ⟨10.1159/000430801⟩. ⟨hal-01273337⟩